Next Article in Journal
Leveraging Spatial Transcriptomics to Decode Craniofacial Development
Previous Article in Journal
Genome-Wide Characterization and Analysis of the FH Gene Family in Medicago truncatula Under Abiotic Stresses
Previous Article in Special Issue
Swedish Genome-Wide Haplotype Association Analysis Suggests Breast Cancer Loci with Varying Risk-Modifying Effects
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Genes
Volume 16
Issue 5
10.3390/genes16050556
genes-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Clinicopathological Characteristics of Ovarian and Breast Cancer in PALB2, RAD51C, and RAD51D Germline Pathogenic Variant Carriers

by
Jella-Rike J. A. H. Spijkervet
1,
L. Lanjouw
1,
L. P. V. Berger
2,
M. D. Dorrius
3,
B. van der Vegt
4,*,† and
G. H. de Bock
1,*,†
1
Department of Epidemiology, University of Groningen, University Medical Center Groningen, 9713 Groningen, The Netherlands
2
Department of Genetics, University of Groningen, University Medical Center Groningen, 9713 Groningen, The Netherlands
3
Department of Radiology, University of Groningen, University Medical Center Groningen, 9713 Groningen, The Netherlands
4
Department of Pathology & Medical Biology, University of Groningen, University Medical Center Groningen, 9713 Groningen, The Netherlands
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Genes 2025, 16(5), 556; https://doi.org/10.3390/genes16050556
Submission received: 2 April 2025 / Revised: 25 April 2025 / Accepted: 28 April 2025 / Published: 2 May 2025
(This article belongs to the Special Issue Genetics and Genomics of Human Breast Cancer)
Browse Figure
Review Reports Versions Notes

Abstract

:
Background/Objectives: Germline pathogenic variants (GPVs) in PALB2, RAD51C, and RAD51D increase breast cancer (BC) and ovarian cancer (OC) risk. Limited data on clinicopathological characteristics of BC and OC in women with these GPVs hamper guideline development. Therefore, this study aims to describe these characteristics in a consecutive series of female PALB2, RAD51C, and RAD51D GPV carriers. Methods: Women with a PALB2, RAD51C, or RAD51D GPV determined before July 2023 at the University Medical Center Groningen were included. Cancer diagnoses were obtained through linkage with the Dutch Nationwide Pathology Databank (Palga). Median onset age and histopathological subtypes were compared to the data of The Netherlands Cancer Registry (NCR). Results: Among 164 GPV carriers (125 PALB2, 30 RAD51C, and 9 RAD51D), 54 BC and 6 OC cases were identified. The median BC onset age was 52 (n = 50), 71 (n = 3), and 43 years (n = 1) for PALB2, RAD51C, and RAD51D, respectively, compared with 62 years in the NCR. No BC histological subtype differences were observed in PALB2 carriers. The populations of RAD51C and RAD51D carriers were too small to compare to NCR data. No OC cases occurred in PALB2 carriers. The median OC onset age was 66 (n = 4) and 56 years (n = 2) for RAD51C and RAD51D carriers, respectively, versus 67 years in the NCR. All RAD51D carriers had high-grade serous carcinoma, compared to 51.5% in the NCR. Conclusions: Differences in onset age and histological subtypes were observed between GPV carriers and national data. Further research on cancer characteristics is needed to optimize counseling and cancer prevention in these women.

1. Introduction

Hereditary factors contribute to approximately 8% of breast cancer (BC) cases and 10–15% of ovarian cancer (OC) cases [1,2]. Germline pathogenic variants (GPVs) in BRCA1 and BRCA2, genes involved in the DNA repair process, are the most common cause of hereditary breast and ovarian cancer (HBOC) [3,4]. In addition, GPVs in the genes CHEK2, ATM, BARD1, PALB2, RAD51C, and RAD51D are associated with an increased risk of BC [5,6,7,8,9,10]. As with BRCA1/2, the latter three genes are also associated with an increased risk of OC, with evidence suggesting that they may lead to an earlier onset of BC and OC compared to the age of onset in the general population [6,9]. Very little is known about the prevalence of GPVs in these genes, but a GPV in the PALB2 gene is found in approximately 1% of women who are genetically tested [11]. Carriers of a PALB2 GPV have a relative risk of 7.2 for BC, with an estimated BC risk of 53% by the age of 80 [12]. Previous research has also suggested that BC in PALB2, RAD51C, and RAD51D GPV carriers is more often associated with triple-negative tumors [13,14]. However, to date, there is a lack of comprehensive data describing other tumor characteristics such as histological subtype and tumor size and stage in PALB2, RAD51C, and RAD51D GPV carriers.
While screening guidelines for BRCA1/2 GPVs are well defined, recommendations remain unclear for PALB2, RAD51C, and RAD51D GPVs. Women carrying a BRCA1/2 GPV can receive intensive breast screening aiming to detect BC at an early stage, starting at age 25 with an annual MRI and consultation. BRCA1 carriers additionally receive bi-annual mammography from 40 to 60 years, whereas BRCA2 carriers receive additional yearly mammography between the ages of 30 and 60 [15,16]. In addition, women may undergo preventive surgery of the breast and/or adnexa [15,16]. For the latter, timely preventive surgery is the only effective method to reduce risk, as screening for ovarian cancer is ineffective [17]. Women with BRCA1 GPVs are advised to undergo this surgery between the ages of 35 and 40, while women with BRCA2 GPVs are advised to do so between the ages of 40 and 45 [18]. In contrast, data on cancer risk for PALB2, RAD51C, and RAD51D GPV carriers are limited and lifetime cancer risks largely depend on both family history and personal risk factors, such as age of menarche, use of oral contraceptives, and the number of children. Dutch guidelines regarding BC surveillance in women with a PALB2 GPV currently recommend yearly MRIs, mammograms, and consultations between the ages of 30 and 60, which are limited to mammograms and consultations from the age of 60 to 75 [19]. Advice for BC screening for RAD51C and RAD51D GPV carriers depends on personal lifetime BC risk estimations calculated by the Canrisk tool [5,20,21,22]. This tool is used to assess the lifetime OC risk in PALB2, RAD51C, and RAD51D GPV carriers as well, leading to personalized advice on risk-reducing salpingo-oophorectomy (RRSO). There is no clear recommendation on the timing of an RRSO in these women.
The limited knowledge of BC and OC risk, age of onset, and associated histological subtypes with these GPVs, complicates evidence-based counseling and preventive care for women with a PALB2, RAD51C, or RAD51D GPV. Therefore, this study aims to describe the age of onset and clinicopathological characteristics of BC and OC patients with a PALB2, RAD51C, or RAD51D GPV and compare these characteristics to national cancer registry data.

2. Materials and Methods

2.1. Setting

According to Dutch guidelines, women diagnosed with BC at a young age or those with risk factors, such as a family history of BC or a Jewish background, are eligible for germline testing [15]. At the University Medical Center Groningen (UMCG), this is performed by the Department of Genetics, in line with Dutch guidelines. The panel currently applied includes the BRCA1, BRCA2, PALB2, CHEK2, ATM, RAD51C, RAD51D, and BARD1 genes. Since 2015, all women with OC have been eligible for germline testing, regardless of risk factors [18]. In 2022, national guidelines changed and now recommend a tumor-first approach for all OC patients, in which pathogenic variants (PV) are tested in tumor tissue. Patients with a PV in the tumor, and those with a family history of OC, are referred for a germline test. The genes analyzed by the Department of Genetics of the UMCG are BRCA1, BRCA2, BRIP2, PALB2, RAD51C, RAD51D, MLH1, MSH2, EPCAM, and MSH6. If a hereditary GPV is detected, relatives are eligible for counseling and genetic testing as well. Further counseling is carried out by a team of specialists, including, among others, a clinical geneticist, a surgical oncologist, a psychologist, and a gynecological oncologist, in the breast–ovarian carcinoma workgroup specializing in hereditary BC and OC cases.

2.2. Study Population

This cohort study included a consecutive series of women (≥18 years) who tested positive for a PALB2, RAD51C, or RAD51D GPV before 15 July 2023 at the UMCG. Women were eligible for genetic testing due to (1) a previous BC or OC diagnosis (in a close relative), or (2) a family member carrying a PALB2, RAD51C, or RAD51D GPV. Women were tested for these GPVs using one of the above-mentioned panels or by testing specifically for the familial PALB2, RAD51C, or RAD51D GPV if applicable. Women with a variant of unknown significance (VUS) in one of these genes were excluded as pathogenicity was not established. Also, clinical guidelines are applicable to GPV carriers and not VUS carriers in PALB2, RAD51C, or RAD51D GPVs. The VUS was not reassessed over the study period. Following Dutch law, the study protocol was proposed to the Medical Ethics Review Board (METc) of the UMCG to review whether human subjects, as decided in the WMO act, were involved. The METc UMCG declared this a non-WMO study as the research does not involve human objects as described in the WMO (Metc 2023/136).

2.3. Study Design

This was an observational, retrospective cohort study. The characteristics of OC and BC tumors of women with a PALB2, RAD51C, or RAD51D GPV were compared with publicly available national cancer data from The Netherlands Cancer Registry (NCR) [23].

2.4. Data Collection

In this study, we collected data on GPV status, date of testing, date of birth (month and year), date of diagnosis of cancer (month and year), histological subtype of cancer, hormone receptor (HR) status, tumor grade, and tumor size at time of diagnosis. Type of GPV, date of genetic test result, and date of birth were collected from the Department of Genetics of the UMCG. Pathology reports from women with a GPV were obtained through linkage with the Dutch Nationwide Pathology Databank (Palga), which provides full coverage of histopathological reports [24]. From the Palga reports, the date of cancer diagnosis, type, histological subtype, HR status, tumor grade, and tumor size at the time of diagnosis were extracted. This research primarily focused on primary breast or ovarian malignancies. For women with multiple cancer diagnoses, the age of onset was determined based on the first occurrence of BC or OC, even if a different type of cancer was diagnosed at an earlier age. In cases where both a breast and ovarian tumor were present, distinct ages of onset were calculated for each malignancy. The tumor size was analyzed at the time of diagnosis. National cancer data were obtained from the NCR and included data about all cancer diagnoses and patient characteristics in The Netherlands. The median age of onset and incidence of the different histological subtypes of BC and OC over the period 2018–2022 were obtained [23].

2.5. Variable Definition and Statistical Analysis

The age of onset of BC or OC was calculated as the number of years between the date of birth (first day of the month of birth) and the date of primary cancer diagnosis (first day of the month of diagnosis). The age of onset was reported as the median, and the interquartile range (IQR) was reported where possible. When the number of cases was insufficient to calculate the IQR, this was reported as not applicable (n.a.). The cancer type and pathohistological subtype were reported as frequencies and percentages. The tumor diameter at the time of diagnosis was reported as the median and IQR. The age of BC and OC onset was compared with national data from the NCR using frequencies and percentages.

3. Results

3.1. Patient Characteristics

A total of 164 women were included. The median age at the time of genetic testing was 53.3 (IQR: 40.0–65.0) years (Table 1). There were 125 (76.2%) women with a PALB2 GPV, 30 (18.3%) women with a RAD51C GPV, and 9 (5.5%) women with a RAD51D GPV. In PALB2 GPV carriers, co-occurrence of a GPV in the CHEK2 gene and NF1 gene was found in four and two cases, respectively. Co-occurrence of a GPV in BRCA1 was present in one RAD51C GPV carrier. A primary tumor was diagnosed in 76 (46.3%) women (Figure 1). As one woman developed both OC and BC, there were 77 primary tumors. Out of the 76 women who developed cancer, there were 54 (71.1%) who developed BC and 6 (7.9%) who developed OC. Seventeen (22.4%) women were diagnosed with another type of primary cancer (Supplementary Table S1). Out of 54 BC patients, 11 (20.4%) women experienced a recurrence of BC. One woman had a recurrence of OC. Of the 76 women with a primary tumor, 65 (85.5%) women were genetically tested after having their cancer diagnosis. Nine (11.8%) women were genetically tested before having their first cancer diagnosis, and for two women, the date of cancer diagnosis was unknown.

3.2. Breast Cancer

Of the 54 women diagnosed with BC, 50 women carried a PALB2 GPV. Three women carried a RAD51C GPV, and one woman carried a RAD51D GPV (Table 2). In women diagnosed with BC, co-occurrence of a CHEK2 GPV was present in one woman carrying a PALB2 GPV. No further co-occurrence of GPVs was present in women diagnosed with BC. The median age of onset of BC in women with a PALB2 GPV was 52.0 (IQR: 42.0–61.5) years. In women with a RAD51C GPV, this was 71.0 years, and for the woman with a RAD51D GPV, this was 43.0 years. The median age of BC onset in the data of the NCR is 62.0 (IQR: 51.0–72.0) years. Of the 50 BC patients with a PALB2 GPV, 45 (90.0%) had an invasive carcinoma of no special type (NST). Invasive lobular carcinoma was diagnosed in four (8.0%) women, and one woman was diagnosed with another subtype. Among the RAD51C carriers, one woman was diagnosed with invasive carcinoma NST, one woman with lobular carcinoma, and one woman with another subtype. The woman with a RAD51D GPV had an invasive lobular carcinoma. In the NCR data, 79.7% of the BCs are invasive carcinoma NST, while 13.0% are invasive lobular carcinoma. A tumor grade was reported for 39 (78.0%) PALB2 GPV carriers; grade 1 five times (12.8%), grade 2 twenty-one times (53.8%), and grade 3 thirteen times (33.3%). In two RAD51C GPV carriers, the tumor grade was reported, with both being grade 1. In the woman carrying a RAD51D GPV, tumor grade 2 was found. The tumor diameter was reported in 31 (62.0%) PALB2 carriers. The median tumor diameter at the time of diagnosis was 15.0 mm (IQR: 11.0–18.0). The tumor diameter at the time of diagnosis was reported in two (66.7%) RAD51C carriers, with a median of 20.5 mm (IQR: n.a.). The tumor diameter of the patient carrying a RAD51D GPV was not reported. Out of all 50 BC patients carrying a PALB2 GPV, HR status was reported for 44 (88.0%) patients, and HER2 status for 39 (78.0%) patients. Out of the 44 patients, 32 (72.7%) had an HR-positive tumor and 3 (7.7%) out of 39 women had a HER2 positive tumor. Out of all 50 BC patients, nine (18.0%) had a triple-negative tumor, and four (8.0%) patients did not have any information on hormone receptor status. All three (100%) patients carrying a RAD51C GPV had an HR-positive and HER2-negative tumor. The RAD51D carrier had a triple-negative tumor. Within the NCR data, 81.7% of the tumors are HR positive, 13.0% HER2 positive, and 11.1% triple negative.

3.3. Ovarian Cancer

None of the PALB2 GPV carriers were diagnosed with OC (Table 2). Out of the six women diagnosed with OC, four carried a RAD51C GPV, and two carried a RAD51D GPV. The median age of onset of OC in the four women with a RAD51C GPV was 66.0 (IQR: 61.0–69.5) years. In the two women with a RAD51D GPV, this was 56.0 years. The median age of OC onset in the NCR data is 67.0 (IQR: 59.0–76.0). Of the four women with a RAD51C GPV, three were diagnosed with a high-grade serous carcinoma. In the RAD51D GPV group, both patients were diagnosed with high-grade serous carcinoma. In the NCR data, 51.5% of the OCs are classified as high-grade serous carcinoma.

4. Discussion

This cohort aimed to describe clinicopathological characteristics in a consecutive series of female PALB2, RAD51C, or RAD51D GPV carriers. In this cohort, the median age of BC onset was lower for PALB2 and RAD51D GPV carriers but higher for RAD51C GPV carriers compared to the data of the NCR. OC was found only in RAD51C and RAD51D GPV carriers, with a lower median age of onset compared to the NCR data. No substantial differences were observed in the age of onset or distribution of OC histological subtypes between women with a PALB2 or RAD51C GPV and the NCR data.
This study reports a lower age of BC onset in PALB2 GPV carriers compared to the NCR data; 52 years compared to 62 years. This is consistent with previous research reporting that more than 50% of PALB2 carriers were diagnosed with BC before the age of 50 years, with an eight to ninefold increased risk under the age of 40 [25]. Another study found a median age of BC onset of 40.25 years (range: 25–53) in PALB2 carriers [26]. Our study observed that the distribution of histological BC subtypes in PALB2 GPV carriers was similar to the distribution in the NCR data. Li et al. found that 75% of all BC cases in PALB2 GPV carriers were of the invasive carcinoma NST subtype, which is lower than our finding of 90.2% [27]. Our study showed that 18.0% of PALB2 carriers had a triple-negative tumor, which is higher than the incidence reported in the NCR data (11.1%). This is in line with a study that found a higher frequency of triple-negative tumors in PALB2 carriers [28].
A large study on BC and OC in RAD51C and RAD51D carriers reported an increased risk of developing BC and/or OC in RAD51C (n = 215) and RAD51D (n = 92) GPV carriers [5]. That study also found an increased risk of early-onset BC and OC, with over half of the BC patients with a RAD51C or RAD51D GPV being under the age of 50 [5]. In contrast, our study found a median BC onset age of 71 years in RAD51C GPV carriers, with the earliest case at 47 years. This could be the result of our small study population. Our finding of a BC onset age of 43 in a RAD51D GPV carrier is consistent with the study of Yang et al., as they found that the BC onset age in RAD51D GPV carriers (n = 30) was below the age of 50 years in over 60% of cases, with over 33% being between the ages of 40 and 49 [5]. A study on OC in RAD51C and RAD51D carriers found that the majority of patients with OC and a RAD51C GPV were above the age of 50 years [29]. Our study showed similar results; a median age of OC onset in RAD51C GPV carriers of 66 years with all cases occurring between 60 and 70. For RAD51D GPV carriers, one study found that more than 75% of OC cases were between the ages 50 and 69 [5], while others found that more than 90% of RAD51D GPV carriers with OC were above the age of 50 [28]. This aligns with our findings of a median OC onset age of 56 in RAD51D GPV carriers. We have found no additional studies on the age of BC and OC onset, or on histological subtypes, in RAD51C or RAD51D GPV carriers. The literature does show that OC in women with a BRCA1 or BRCA2 GPV is generally associated with high-grade serous ovarian carcinoma [30]. We found 75% and 100% of OC cases of the high-grade serous subtype in women with a RAD51C and RAD51D GPV, respectively. RAD51C and RAD51D genes are, similar to BRCA1 and BRCA2, involved in homologous recombination repair pathways, possibly implying that there is an association between these GPVs and high-grade serous OC as well.

Strengths and Limitations

A strong point of this study is the inclusion of a consecutive series of women carrying a PALB2, RAD51C, or RAD51D GPV who were all genetically tested in a specialized center with a strict protocol. A second strength of this study is the linkage with the pathology database, Palga, as this ensured 100% coverage of pathological reports in The Netherlands. This way, patients diagnosed with cancer outside our institution were also included. Also, analyzing the tumor diameter, tumor grade, histological subtype, and receptor status in BC patients led to a complete overview of the histopathological characteristics of these groups. Lastly, to our knowledge, this is the first study investigating the histological subtype of OC in RAD51C and RAD51D GPV carriers. However, several limitations must also be considered. First, like most studies on RAD51C and RAD51D GPVs, the number of women included was relatively low. Subgroup and association analysis could not be performed due to this small sample size, which limited the ability to draw conclusions on differences between these groups. Future studies, preferably multi-center, may overcome this limitation by including a larger cohort. Secondly, the testing and screening protocols determined which women were identified and followed, thereby potentially influencing the observed age of diagnosis through detection bias. Although our cohort represents a clinically relevant population, it may have resulted in a younger observed age of onset compared to what might have been seen in an unselected group of PALB2, RAD51C, or RAD51D GPV carriers.
In this consecutive series, a lower age of BC onset was seen in women with a PALB2 GPV compared to the NCR data. In women with a RAD51C GPV, a higher age of BC onset and a lower age of OC onset were observed compared to the NCR data. A lower age of onset was observed for both BC and OC in women with a RAD51D GPV compared to the NCR data. Additional studies with a larger sample size, for example, by pooling existing cohorts, are required to study the histological subtypes and age of onset in women with a PALB2, RAD51C, or RAD51D GPV to draw more reliable conclusions.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/genes16050556/s1, Table S1: Prevalence of primary cancer types by GPV.

Author Contributions

Conceptualization, J.-R.J.A.H.S., L.L., L.P.V.B. and G.H.d.B. methodology, J.-R.J.A.H.S., L.L. and G.H.d.B.; formal analysis, J.-R.J.A.H.S. and L.L.; investigation, J.-R.J.A.H.S.; data curation, L.L., L.P.V.B. and B.v.d.V.; writing—original draft preparation, J.-R.J.A.H.S.; writing—review and editing, L.L., L.P.V.B., B.v.d.V., M.D.D. and G.H.d.B.; supervision, L.L. and G.H.d.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki and was approved by the Medical Ethics Review Board of the University Medical Center Groningen (Metc 2023/136, 6 March 2023).

Informed Consent Statement

Patient consent was waived according to local regulations as no privacy sensitive data were recorded.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Acknowledgments

The authors thank the registration team of The Netherlands Comprehensive Cancer Organisation (IKNL) for the collection of data for The Netherlands Cancer Registry as well as IKNL staff for scientific advice.

Conflicts of Interest

BvdV: honoraria received by UMCG for expertise or scientific advisory board/consultancy (on request)—Visiopharm, Philips, MSD/Merck, and Daiichi-Sankyo/AstraZeneca; speaker’s fee from Visiopharm, Diaceutics, and MSD/Merck. Research grants from OWKIN, GE Healthcare, and Roche. Personal fees from DEKRA. The funders had no role in the design of this study, in the collection, analyses, or interpretation of the data, in the writing of this manuscript, or in the decision to publish the results.

Abbreviations

The following abbreviations are used in this manuscript:
GPV germline pathogenic variant
BCbreast cancer
OC ovarian cancer
NCRnational cancer registry
RRSOrisk-reducing salpingo-oophorectomy
UMCGUniversity Medical Center Groningen
PVpathogenic variant
METcMedical Ethics Review Board
HRhormone receptor
NSTno special type

References

  1. Russo, A.; Calò, V.; Bruno, L.; Rizzo, S.; Bazan, V.; Di Fede, G. Hereditary Ovarian Cancer. Crit. Rev. Oncol. Hematol. 2009, 69, 28–44. [Google Scholar] [CrossRef] [PubMed]
  2. Yoshida, R. Hereditary Breast and Ovarian Cancer (HBOC): Review of Its Molecular Characteristics, Screening, Treatment, and Prognosis. Breast Cancer 2021, 28, 1167–1180. [Google Scholar] [CrossRef] [PubMed]
  3. Paul, A.; Paul, S. The Breast Cancer Susceptibility Genes (BRCA) in Breast and Ovarian Cancers. Front. Biosci. Landmark Ed. 2014, 19, 605–618. [Google Scholar] [CrossRef]
  4. Varol, U.; Kucukzeybek, Y.; Alacacioglu, A.; Somali, I.; Altun, Z.; Aktas, S.; Oktay Tarhan, M. BRCA Genes: BRCA1 and BRCA2. J. Balk. Union Oncol. 2018, 23, 862–866. [Google Scholar]
  5. Yang, X.; Song, H.; Leslie, G.; Engel, C.; Hahnen, E.; Auber, B.; Horváth, J.; Kast, K.; Niederacher, D.; Turnbull, C.; et al. Ovarian and Breast Cancer Risks Associated with Pathogenic Variants in RAD51C and RAD51D. J. Natl. Cancer Inst. 2020, 112, 1242–1250. [Google Scholar] [CrossRef]
  6. Breast Cancer Association Consortium; Dorling, L.; Carvalho, S.; Allen, J.; González-Neira, A.; Luccarini, C.; Wahlström, C.; Pooley, K.A.; Parsons, M.T.; Fortuno, C.; et al. Breast Cancer Risk Genes—Association Analysis in More than 113,000 Women. N. Engl. J. Med. 2021, 384, 428–439. [Google Scholar] [CrossRef]
  7. Potapova, A.; Hoffman, A.M.; Godwin, A.K.; Al-Saleem, T.; Cairns, P. Promoter Hypermethylation of the PALB2 Susceptibility Gene in Inherited and Sporadic Breast and Ovarian Cancer. Cancer Res. 2008, 68, 998–1002. [Google Scholar] [CrossRef]
  8. Pylkäs, K.; Erkko, H.; Nikkilä, J.; Sólyom, S.; Winqvist, R. Analysis of Large Deletions in BRCA1, BRCA2, and PALB2 Genes in Finnish Breast and Ovarian Cancer Families. BMC Cancer 2008, 8, 146. [Google Scholar] [CrossRef]
  9. Meindl, A.; Hellebrand, H.; Wiek, C.; Erven, V.; Wappenschmidt, B.; Niederacher, D.; Freund, M.; Lichtner, P.; Hartmann, L.; Schaal, H.; et al. Germline Mutations in Breast and Ovarian Cancer Pedigrees Establish RAD51C as a Human Cancer Susceptibility Gene. Nat. Genet. 2010, 42, 410–414. [Google Scholar] [CrossRef]
  10. Loveday, C.; Turnbull, C.; Ramsay, E.; Hughes, D.; Ruark, E.; Frankum, J.R.; Bowden, G.; Kalmyrzaev, B.; Warren-Perry, M.; Snape, K.; et al. Germline Mutations in RAD51D Confer Susceptibility to Ovarian Cancer. Nat. Genet. 2011, 43, 879–882. [Google Scholar] [CrossRef]
  11. Kanker in de Familie, PALB2. Available online: https://kankerindefamilie.nl/kanker-in-de-familie/erfelijke-aanleg-borstkanker/palb2/#:~:text=Een%20afwijking%20(mutatie)%20in%20het,in%20het%20PALB2%2Dgen%20gevonden (accessed on 16 April 2025).
  12. Yang, X.; Leslie, G.; Doroszuk, A.; Schneider, S.; Allen, J.; Decker, B.; Dunning, A.M.; Redman, J.; Scarth, J.; Plaskocinska, I.; et al. Cancer Risks Associated with Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J. Clin. Oncol. 2020, 38, 674–685. [Google Scholar] [CrossRef] [PubMed]
  13. Shimelis, H.; LaDuca, H.; Hu, C.; Hart, S.N.; Na, J.; Thomas, A.; Akinhanmi, M.; Moore, R.M.; Brauch, H.; Cox, A.; et al. Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. J. Natl. Cancer Inst. 2018, 110, 855–862. [Google Scholar] [CrossRef]
  14. Breast Cancer Association Consortium; Mavaddat, N.; Dorling, L.; Carvalho, S.; Allen, J.; González-Neira, A.; Keeman, R.; Bolla, M.K.; Dennis, J.; Wang, Q.; et al. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncol. 2022, 8, e216744. [Google Scholar] [CrossRef] [PubMed]
  15. Richtlijnendatabase. Screening Buiten Het BVO. Available online: https://richtlijnendatabase.nl/richtlijn/borstkanker/screening/screening_buiten_het_bvo/screening_buiten_het_bvo.html (accessed on 8 January 2025).
  16. Ramus, S.J.; Song, H.; Dicks, E.; Tyrer, J.P.; Rosenthal, A.N.; Intermaggio, M.P.; Fraser, L.; Gentry-Maharaj, A.; Hayward, J.; Philpott, S.; et al. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women with Ovarian Cancer. J. Natl. Cancer Inst. 2015, 107, djv214. [Google Scholar] [CrossRef] [PubMed]
  17. Van der Velde, N.M.; Mourits, M.J.; Arts, H.J.; de Vries, J.; Leegte, B.K.; Dijkhuis, G.; Oosterwijk, J.C.; de Bock, G.H. Time to Stop Ovarian Cancer Screening in BRCA1/2 Mutation Carriers? Int. J. Cancer 2009, 124, 919–923. [Google Scholar] [CrossRef]
  18. Richtlijnendatabase. Erfelijk en Familiair Ovariumcarcinoom. Available online: https://richtlijnendatabase.nl/richtlijn/erfelijk_en_familiair_ovariumcarcinoom/erfelijk_en_familiair_ovariumcarcinoom_algemeen.html. (accessed on 8 January 2025).
  19. VKGN. [Erfelijke en Familiare Tumoren, Richtlijnen Voor Diagnostiek en Preventie]. VKGN. Available online: https://vkgn.stoet.nl/index.php?article_id=69 (accessed on 17 March 2025).
  20. Lee, A.; Mavaddat, N.; Wilcox, A.N.; Cunningham, A.P.; Carver, T.; Hartley, S.; Babb de Villiers, C.; Izquierdo, A.; Simard, J.; Schmidt, M.K.; et al. BOADICEA: A Comprehensive Breast Cancer Risk Prediction Model Incorporating Genetic and Nongenetic Risk Factors. Genet. Med. 2019, 21, 1708–1718. [Google Scholar] [CrossRef]
  21. Carver, T.; Hartley, S.; Lee, A.; Cunningham, A.P.; Archer, S.; Babb de Villiers, C.; Roberts, J.; Ruston, R.; Walter, F.M.; Tischkowitz, M.; et al. CanRisk Tool—A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants. Cancer Epidemiol. Biomark. Prev. 2021, 30, 469–473. [Google Scholar] [CrossRef]
  22. Archer, S.; Babb de Villiers, C.; Scheibl, F.; Carver, T.; Hartley, S.; Lee, A.; Cunningham, A.P.; Easton, D.F.; McIntosh, J.G.; Emery, J.; et al. Evaluating Clinician Acceptability of the Prototype CanRisk Tool for Predicting Risk of Breast and Ovarian Cancer: A Multi-Methods Study. PLoS ONE 2020, 15, e0229999. [Google Scholar] [CrossRef]
  23. NKR Cijfers. Incidentie per Jaar. Available online: https://nkr-cijfers.iknl.nl/viewer/incidentie-per-jaar?language=nl_NL&viewerId=3b55d752-ce1a-4809-89d9-8421febdb1f4 (accessed on 7 February 2025).
  24. Casparie, M.; Tiebosch, A.T.; Burger, G.; Blauwgeers, H.; van de Pol, A.; van Krieken, J.H.; Meijer, G.A. Pathology Databanking and Biobanking in The Netherlands, a Central Role for PALGA, the Nationwide Histopathology and Cytopathology Data Network and Archive. Cell. Oncol. 2007, 29, 19–24. [Google Scholar] [CrossRef]
  25. Antoniou, A.C.; Casadei, S.; Heikkinen, T.; Barrowdale, D.; Pylkäs, K.; Roberts, J.; Lee, A.; Subramanian, D.; De Leeneer, K.; Fostira, F.; et al. Breast-Cancer Risk in Families with Mutations in PALB2. N. Engl. J. Med. 2014, 371, 497–506. [Google Scholar] [CrossRef]
  26. Tibiletti, M.G.; Carnevali, I.; Facchi, S.; Libera, L.; Chiappa, C.; Sessa, F.; Rosa, S.; Rovera, F. PALB2 Analysis in the Diagnostic Process of Breast Cancer: An Italian Monocentric Experience. Tumori J. 2024, 24, 3008916241290738. [Google Scholar] [CrossRef] [PubMed]
  27. Li, J.; He, P.; Cai, Q.; Chen, L.; Wang, Y.; Cai, W.; Qiu, Y.; Liu, S.; Guo, W.; Chen, M.; et al. Spectrum and Characteristics of Germline PALB2 Pathogenic Variants in 1556 Early-Onset Breast Cancer Patients in China. J. Cancer Res. Clin. Oncol. 2024, 150, 322. [Google Scholar] [CrossRef] [PubMed]
  28. Kansu, B.; Gardner, J.; Price-Tate, R.; Murch, O.; Murray, A. BRCA Gene Testing in Women with High-Grade Serous Ovarian Carcinoma. J. Obstet. Gynaecol. 2021, 41, 962–965. [Google Scholar] [CrossRef] [PubMed]
  29. Song, H.; Dicks, E.; Ramus, S.J.; Tyrer, J.P.; Intermaggio, M.P.; Hayward, J.; Edlund, C.K.; Conti, D.; Harrington, P.; Fraser, L.; et al. Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. J. Clin. Oncol. 2015, 33, 2901–2907. [Google Scholar] [CrossRef]
  30. Labidi-Galy, S.I.; Papp, E.; Hallberg, D.; Niknafs, N.; Adleff, V.; Noe, M.; Bhattacharya, R.; Novak, M.; Jones, S.; Phallen, J.; et al. High Grade Serous Ovarian Carcinomas Originate in the Fallopian Tube. Nat. Commun. 2017, 8, 1093. [Google Scholar] [CrossRef]
Genes 16 00556 g001
Figure 1. Flowchart of Palga linkage results. * Patients diagnosed with cancer in The Netherlands can be linked to Palga; without a cancer diagnosis, there is no linkage with Palga.
Figure 1. Flowchart of Palga linkage results. * Patients diagnosed with cancer in The Netherlands can be linked to Palga; without a cancer diagnosis, there is no linkage with Palga.
Genes 16 00556 g001
Table 1. Characteristics of female GPV carriers and their tumors (n = 164) *.
Table 1. Characteristics of female GPV carriers and their tumors (n = 164) *.
CharacteristicsTotal
N = 164
Age at the time of genetic testing in years (median (IQR))54.0 (40–65)
Type of mutation
  PALB2125 (76.2%)
  RAD51C30 (18.3%)
  RAD51D9 (5.5%)
Women with a diagnosis of primary cancer **76 (%)
  Breast53 (69.7%)
  Ovarian5 (6.6%)
  Breast and ovarian1 (1.3%)
  Other17 (22.4%)
Second diagnosis/Recurrence12
  Breast11
  Ovarian1
Sequence of genetic testing and cancer diagnosis76 (%)
  Cancer diagnosed before genetic testing65 (85.5%)
  Cancer diagnosed after genetic testing9 (11.8%)
  Unknown ***2 (2.6%)
* Presented are n (%) unless specified otherwise; ** one patient had both primary OC and BC diagnosis; *** for two patients, the exact date of cancer diagnosis was unknown.
Table 2. Characteristics of breast and ovarian cancer within GPV groups.
Table 2. Characteristics of breast and ovarian cancer within GPV groups.
PALB2RAD51CRAD51DNCR Data
Breast cancer (n)503 *1
Age at the time of diagnosis (median (IQR))52 (42–61.5)71 (n.a.) **43 (n.a.) **62 (51–72)
Histological subtype
  Invasive carcinoma
NST		45 (90.0%)1 (33.3%)079.7%
  Invasive lobular
carcinoma		4 (8.0%)1 (33.3%)1 (100%)13.0%
  Other subtypes1 (2.0%)1 (33.3%)07.3%
Tumor grade
  15 (12.8%)2 (100%)0-
  221 (53.8%)00-
  313 (33.3%)01 (100%)-
  Not reported11 (22.0%)1 (33.3%)0-
Tumor diameter at the time of diagnosis (median (IQR))15.0 mm (11.0–18.0)20.5 mm (n.a.) **Unknown-
Hormone receptor status
  HR +32 (72.7%)3 (100%)081.7%
  HER2 +3 (7.7%)0013.0%
  Triple negative9 (18.0%)01 (100%)11.1%
  Unknown4 (8.0%)00
Ovarian cancer (n)04 *2
Age at the time of diagnosis (median (IQR))-66 (61–69.5)56 (n.a.) **67 (59–76)
Histological subtype
  High-grade serous-3 (75.0%)2 (100%)51.5%
  Low-grade serous---4.9%
  Endometroid---5.9%
  Clear cell---5.2%
  Mucinous---5.7%
  Carcinosarcoma---2.0%
  Other-1 (25.0%)-24.7%
Bold font was used to differentiate between breast and ovarian cancer patients with PALB2, RAD51C and RAD51D germline pathogenic variants. * One patient had both BC and OC as the primary tumor. ** n.a.: not applicable; cannot be calculated due to small number of patients.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Spijkervet, J.-R.J.A.H.; Lanjouw, L.; Berger, L.P.V.; Dorrius, M.D.; van der Vegt, B.; de Bock, G.H. Clinicopathological Characteristics of Ovarian and Breast Cancer in PALB2, RAD51C, and RAD51D Germline Pathogenic Variant Carriers. Genes 2025, 16, 556. https://doi.org/10.3390/genes16050556

AMA Style

Spijkervet J-RJAH, Lanjouw L, Berger LPV, Dorrius MD, van der Vegt B, de Bock GH. Clinicopathological Characteristics of Ovarian and Breast Cancer in PALB2, RAD51C, and RAD51D Germline Pathogenic Variant Carriers. Genes. 2025; 16(5):556. https://doi.org/10.3390/genes16050556

Chicago/Turabian Style

Spijkervet, Jella-Rike J. A. H., L. Lanjouw, L. P. V. Berger, M. D. Dorrius, B. van der Vegt, and G. H. de Bock. 2025. "Clinicopathological Characteristics of Ovarian and Breast Cancer in PALB2, RAD51C, and RAD51D Germline Pathogenic Variant Carriers" Genes 16, no. 5: 556. https://doi.org/10.3390/genes16050556

APA Style

Spijkervet, J.-R. J. A. H., Lanjouw, L., Berger, L. P. V., Dorrius, M. D., van der Vegt, B., & de Bock, G. H. (2025). Clinicopathological Characteristics of Ovarian and Breast Cancer in PALB2, RAD51C, and RAD51D Germline Pathogenic Variant Carriers. Genes, 16(5), 556. https://doi.org/10.3390/genes16050556

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop